150 Years
Science For A
Better Life

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Not intended for U.S. and UK Media

49th Annual Meeting of the American Society of Clinical Oncology (ASCO):

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

- First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session
- Data presentations for three oncology products across five tumor types

---

Leverkusen, Germany, May 16, 2013 – Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 – June 4, in Chicago, IL (USA). These data, including the first presentation of the results from the pivotal Phase III DECISION trial of Nexavar in patients with radioactive iodine-refractory differentiated thyroid cancer, showcase Bayer's commitment to developing effective treatments for difficult-to-treat cancers.

"Bayer's presence at ASCO this year reflects both the strong foundation of our oncology franchise, heralded by the expanded clinical success of Nexavar, and the innovations we are continuing to deliver in tumor types with high unmet need," said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "Since last year's ASCO meeting, our oncology franchise has grown to include two additional products in three indications. We're proud of this landmark year which is a result of our ongoing commitment to making bold investments in areas where

we can truly make a difference for patients."

Notable studies evaluating Bayer's oncology products and compounds at ASCO include:

Sorafenib (Nexavar)

- *Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial*
    - Abstract #4, Plenary Abstract Session
    - Sunday, June 2, 3:20 - 3:35 PM, N Hall B1
- *Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction*
    - Abstract #4126, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
    - Sunday, June 2, 8:00 - 11:45 AM, S Hall A2

Regorafenib (Stivarga)

- *Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.*
    - Abstract #10503, Oral Abstract Session: Sarcoma
    - Monday, June 3, 3:45 - 4:00 PM, S100bc
- *Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics*
    - Abstract # 10551, General Poster Session: Sarcoma
    - Saturday, June 1, 1:15 - 5:00 PM, S Hall A2
- *Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study*
    - Abstract # 3637, General Poster Session: Gastrointestinal (Colorectal) Cancer
    - Sunday, June 2, 8:00 - 11:45 AM, S Hall A2
- *Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial*
    - Abstract # 3636, General Poster Session: Gastrointestinal (Colorectal) Cancer
    - Sunday, June 2, 8:00 - 11:45 AM, S Hall A2

- *Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial*
    - Abstract # TPS4163, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
    - Sunday, June 2, 8:00 - 11:45 AM, S Hall A2
- *Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer*
    - Abstract #3514, Poster Discussion Session: Gastrointestinal (Colorectal) Cancer
    - Tuesday, June 4, 8:00 AM - 12:00 PM, S405

Radium 223 dichloride (Xofigo)

- *Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study.*
    - Abstract #5021, Poster Discussion Session, Genitourinary (Prostate) Cancer
    - Saturday, June 1, 8:00 AM - 12:00 PM, E450a, Poster Board #13
- *Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial*
    - Abstract #5060, General Poster Session: Genitourinary (Prostate) Cancer
    - Monday, June 3, 8:00 - 11:45 AM, S Hall A2
- *Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial*
    - Abstract #5068, General Poster Session: Genitourinary (Prostate) Cancer
    - Monday, June 3, 8:00 - 11:45 AM, S Hall A2
- *Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases*
    - Abstract #5038, General Poster Session: Genitourinary (Prostate) Cancer
    - Monday, June 3, 8:00 - 11:45 AM, S Hall A2
- *Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes*
    - Abstract #5080, General Poster Session: Genitourinary (Prostate) Cancer
    - Monday, June 3, 8:00 - 11:45 AM, S Hall A2

About Oncology at Bayer

Bayer is committed to delivering *science for a better life* by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.